Efifcacy of lamivudine in chronic hepatitis B antiviral therapy
- VernacularTitle:慢性乙型肝炎应用拉米夫定抗病毒治疗的疗效分析
- Author:
Lianyue ZHENG
;
Aiping TAO
- Publication Type:Journal Article
- Keywords:
chronic hepatitis B;
lamivudine;
entecavir;
conversion rate;
recovery rate
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):135-136
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efifcacy of lamivudine in chronic hepatitis B antiviral therapy. Methods 78 cases with chronic hepatitis B patients from January 2012 to December 2012 collected in People's Hospital of Deqing County were observed and randomly divided into experimental group and control group, 39 cases in each group. Control group were treated with entecavir , and experimental group with lamivudine. The negative rate of hepatitis B virus, hepatitis B virus surface antigen (hepatitis B surface antigen, HBsAg) seroconversion rates and alanine aminotransferase (Alamine aminotransferase, ALT) recovery rate after 6 weeks, 12 weeks , 18 weeks , 24 weeks of the two groups were compared. Results The negative rate of hepatitis B virus, ALT recovery rates in control group after 6 weeks, 12 weeks , 18 weeks, 24 weeks treatment were better than experimental group , the differences were statistically signiifcant(P<0.05). There was no signiifcant differences in the rate of HBsAg seroconversion at week 6 weeks, 12 weeks, 18 weeks, 24 weeks between two groups. Conclusion Lamivudine antiviral ,has acceptable clinical efifcacy in treatment for chronic hepatitis B, and still has a certain gap with entecavir, but it has an appropriate price, which may be more suitable for patients in economic. So choose which medicine in clinical application should be in combination with the practical situation of patients.
